Stable IL-10: A New Therapeutic that Promotes Tumor Immunity
Menée sur des modèles murins, cette étude montre qu'un traitement à l'interleukine 10 pégylée permet d'activer la surveillance immunitaire des tumeurs et de réduire la croissance tumorale
In this issue of Cancer Cell, Mumm et al. demonstrate that pegylated IL-10 increases CD8+ T cell numbers, IFN-³ secretion, and cytotoxicity in established tumors, enhancing antigen presentation machinery and suppressing tumor growth. This approach may enhance T cell immune responses in cancers with reduced T cell infiltration.
Cancer cell , commentaire, 2010